S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Indonesia says it has seized Iranian and Panamanian tankers
The Latest: France faces 3rd lockdown if curfew not enough
Trapped for 2 weeks, 11 workers rescued from China gold mine
White House begins talks with lawmakers on COVID-19 relief
pixel
Average US price of gas up 10 cents a gallon to $2.45
The Latest: Australia approves coronavirus vaccine
The Latest: EU: Drug firms must fulfill vaccine contracts
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Indonesia says it has seized Iranian and Panamanian tankers
The Latest: France faces 3rd lockdown if curfew not enough
Trapped for 2 weeks, 11 workers rescued from China gold mine
White House begins talks with lawmakers on COVID-19 relief
pixel
Average US price of gas up 10 cents a gallon to $2.45
The Latest: Australia approves coronavirus vaccine
The Latest: EU: Drug firms must fulfill vaccine contracts
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Indonesia says it has seized Iranian and Panamanian tankers
The Latest: France faces 3rd lockdown if curfew not enough
Trapped for 2 weeks, 11 workers rescued from China gold mine
White House begins talks with lawmakers on COVID-19 relief
pixel
Average US price of gas up 10 cents a gallon to $2.45
The Latest: Australia approves coronavirus vaccine
The Latest: EU: Drug firms must fulfill vaccine contracts
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Indonesia says it has seized Iranian and Panamanian tankers
The Latest: France faces 3rd lockdown if curfew not enough
Trapped for 2 weeks, 11 workers rescued from China gold mine
White House begins talks with lawmakers on COVID-19 relief
pixel
Average US price of gas up 10 cents a gallon to $2.45
The Latest: Australia approves coronavirus vaccine
The Latest: EU: Drug firms must fulfill vaccine contracts
Log in
OTCMKTS:NSPX

Inspyr Therapeutics Stock Forecast, Price & News

$0.0093
0.00 (0.00 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.01
Now: $0.01▼
$0.01
50-Day Range
$0.01
MA: $0.01▼
$0.01
52-Week Range
$0.00
Now: $0.01▼
$1.13
Volume26.94 million shs
Average Volume25.53 million shs
Market Capitalization$1.40 million
P/E RatioN/A
Dividend YieldN/A
Beta-16.55
Inspyr Therapeutics, Inc., clinical-stage pharmaceutical company, focuses on the development of therapeutics for the treatment of diseases. It focuses on a pipeline of small molecule adenosine receptor modulators, such as A2B antagonists, dual A2A/A2B antagonists, and A2A agonists. The company was formerly known as GenSpera Inc. and changed its name to Inspyr Therapeutics, Inc. in August 2016. Inspyr Therapeutics, Inc. was founded in 2003 and is based in Westlake Village, California.

MarketRank™

Overall MarketRank™

0.48 out of 5 stars

Medical Sector

1555th out of 1,923 stocks

Pharmaceutical Preparations Industry

671st out of 773 stocks

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:NSPX
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.genspera.com
Phone818-661-6302
Employees1

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value($14.05) per share
Price / Book0.00

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-930,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-298.11%

Miscellaneous

Outstanding Shares150,000,000
Market Cap$1.40 million
Next Earnings DateN/A
OptionableNot Optionable
$0.0093
0.00 (0.00 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NSPX News and Ratings via Email

Sign-up to receive the latest news and ratings for NSPX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Inspyr Therapeutics (OTCMKTS:NSPX) Frequently Asked Questions

How has Inspyr Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Inspyr Therapeutics' stock was trading at $0.0019 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NSPX stock has increased by 389.5% and is now trading at $0.0093.
View which stocks have been most impacted by COVID-19.

What stocks does MarketBeat like better than Inspyr Therapeutics?

Wall Street analysts have given Inspyr Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Inspyr Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Inspyr Therapeutics' earnings last quarter?

Inspyr Therapeutics, Inc. (OTCMKTS:NSPX) issued its earnings results on Monday, August, 14th. The company reported ($0.35) earnings per share for the quarter.
View Inspyr Therapeutics' earnings history.

Who are some of Inspyr Therapeutics' key competitors?

Some companies that are related to Inspyr Therapeutics include Nexien BioPharma (NXEN), Acura Pharmaceuticals (ACUR), Helix BioMedix (HXBM), Benitec Biopharma (BNTC), Wize Pharma (WIZP), Intellipharmaceutics International (IPCIF), BriaCell Therapeutics (BCTXF), Innovus Pharmaceuticals (INNV), International Stem Cell (ISCO), Akorn (AKRXQ), Amarantus BioScience (AMBS), Innovus Pharmaceuticals (INNVD), Pivotal Therapeutics (PVTTF), Capstone Therapeutics (CAPS) and Boston Therapeutics (BTHE).
View all of NSPX's competitors.

What other stocks do shareholders of Inspyr Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inspyr Therapeutics investors own include Hon Hai Precision Industry (HNHPF), iBio (IBIO), Knight-Swift Transportation (KNX), Danaher (DHR), Co-Diagnostics (CODX), Creative Medical Technology (CELZ), Cleveland BioLabs (CBLI), Cloudcall Group plc (CALL.L) (CALL), Blink Charging (BLNK) and BIO-key International (BKYI).

Who are Inspyr Therapeutics' key executives?

Inspyr Therapeutics' management team includes the following people:
  • Mr. Michael Cain, Interim CEO, CFO, Pres & Exec. Director (Age 37)
  • Dr. John T. Isaacs, Co-Founder, Chairman of Scientific Advisory Board & Chief Scientific Advisor
  • Dr. Samuel R. Denmeade, Co-Founder, Chief Clinical Advisor and Member of Scientific Advisory Board

What is Inspyr Therapeutics' stock symbol?

Inspyr Therapeutics trades on the OTCMKTS under the ticker symbol "NSPX."

How do I buy shares of Inspyr Therapeutics?

Shares of NSPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Inspyr Therapeutics' stock price today?

One share of NSPX stock can currently be purchased for approximately $0.01.

How big of a company is Inspyr Therapeutics?

Inspyr Therapeutics has a market capitalization of $1.40 million. Inspyr Therapeutics employs 1 workers across the globe.

What is Inspyr Therapeutics' official website?

The official website for Inspyr Therapeutics is www.genspera.com.

How can I contact Inspyr Therapeutics?

Inspyr Therapeutics' mailing address is 31200 VIA COLINAS SUITE 200, WESTLAKE VILLAGE CA, 91362. The company can be reached via phone at 818-661-6302 or via email at [email protected]

This page was last updated on 1/24/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.